PNGM Historical Cash Flow
| PNGM Stock | USD 0.0001 0.00 0.00% |
Analysis of Er Therapeutics cash flow over time is an excellent tool to project Er Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Borrowings of 41.2 K or Total Cashflows From Investing Activities of 59.2 K as it is a great indicator of Er Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Er Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Er Therapeutics is a good buy for the upcoming year.
PNGM |
About PNGM Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in PNGM balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which PNGM's non-liquid assets can be easily converted into cash.
Er Therapeutics Cash Flow Chart
Add Fundamental
Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Most accounts from Er Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Er Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Er Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.At this time, Er Therapeutics' Other Cashflows From Investing Activities is very stable compared to the past year. As of the 25th of December 2024, Change To Netincome is likely to grow to about 129.8 K, though Depreciation is likely to grow to (12.9 K).
| 2010 | 2011 | 2023 | 2024 (projected) | Change To Liabilities | 9.9K | 148.2K | 170.4K | 88.5K | Change To Netincome | 2.1K | 107.5K | 123.6K | 129.8K |
Er Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Er Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Er Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.